Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05933174 · ClinicalTrials.gov registry record · NA

Promoting Alternatives to Sulfonylureas to Improve Patient Safety in Type 2 Diabetes

A NA study of Type 2 Diabetes, sponsored by Ian J. Neeland, MD.

Recruiting
Registry status
NA
Development phase
220
Enrollment target
1
Study location

NCT05933174: Recruiting NA study of Type 2 Diabetes, sponsored by Ian J. Neeland, MD.

NCT05933174 is a NA study of Type 2 Diabetes that is actively recruiting participants, run by Ian J. Neeland, MD. The registered enrollment target is 220 participants, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05933174, a NA study of Type 2 Diabetes, is actively recruiting participants, sponsored by Ian J. Neeland, MD.

RECRUITING
Registry status
NA
Development phase
220 participants
Enrollment target
1
Study location

Study Summary

Sulfonylurea medications are unsafe for older patients with diabetes. They are associated not only with hypoglycemia, but also with falls and increased cardiovascular risk. Yet they continue to be prescribed frequently. Indeed, older adults with type 2 diabetes, who are especially prone to adverse effects, are more likely to be prescribed sulfonylureas than younger patients. This is unfortunate since over the past several years, newer, safer, and more effective classes of medications (GLP-1 agonists and SGLT2-inhibitors) have emerged. The investigators acknowledge that sulfonylureas are inexpensive and that their low cost is a driver of continued use. However, the investigators believe patients and providers should have discussions about the risks of sulfonylureas and safer and more effective alternatives, to make diabetes care safer overall in ambulatory settings. Our research is designed to promote such discussions. The investigators will first identify patients taking sulfonylureas regularly. Next, using recommendations from AHRQ and the Canadian Deprescribing Network, the investigators will empower patients to discuss their medications with their providers through a simple question prompt sheet. Patients will be divided into an intervention group which receives explicit prompting questions, and a control group that receives a general brochure on diabetes medications. Health care providers will receive education about newer diabetes medications through case-based discussions and academic detailing. Finally the investigators will measure key outcomes including the proportion of patients who have discussions about sulfonylureas and alternatives, rates of discontinuation, and measures of control of diabetes and associated cardiovascular risks. The investigators will also evaluate the experiences of patients and providers qualitatively through brief, semi-structured interviews. Should our multi-faceted, patient-oriented intervention prove effective in promoting discu

Primary Outcome

Proportion of patients who had a conversation with their primary care provider about SU use and alternatives for their diabetes management

Conditions Studied

Interventions

  • OTHER Prompt-sheet
  • OTHER Usual education

Study Locations (1)

Ohio

  • University Hospitals Cleveland Medical Center - Cleveland

Trial Details

FieldValue
Enrollment Target 220 participants
Start Date 2023-10-01
Est. Completion 2026-06-30
Phase NA
Ian J. Neeland, MD

4 total trials

What NCT05933174 shows while recruiting

NCT05933174 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (94% lower).

The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Prompt-sheet is the first listed.

NCT05933174 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT05933174 about?

NCT05933174 is a clinical study titled "Promoting Alternatives to Sulfonylureas to Improve Patient Safety in Type 2 Diabetes". Sulfonylurea medications are unsafe for older patients with diabetes. They are associated not only with hypoglycemia, but also with falls and increased cardiovascular risk. Yet they continue to be prescribed frequently. Indeed, older adults with type 2 diabetes, who are especially prone to adverse e...

What is the current status of trial NCT05933174?

This trial is currently recruiting. It is a NA study. The enrollment target is 220 participants. The study started on 2023-10-01. Estimated completion is 2026-06-30.

What conditions does trial NCT05933174 study?

This clinical trial studies the following conditions: Type 2 Diabetes.

What interventions are being tested in trial NCT05933174?

The interventions under investigation include: Prompt-sheet (OTHER), Usual education (OTHER).

Who is sponsoring clinical trial NCT05933174?

This trial is sponsored by Ian J. Neeland, MD, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05933174 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05933174's enrollment target sits among peer trials

220 89th of 327 higher than 239 of 327 other Type 2 Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00920972 · 220 participants · Phase 1

    Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases

  • NCT01851642 · 220 participants

    Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs

  • NCT02582021 · 220 participants

    WISE CVD - Continuation (WISE HFpEF)

  • NCT04067830 · 220 participants · Phase 2

    Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05933174, the US trial registry maintained by the National Library of Medicine. NCT05933174 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.